The case for & against
Bull & Bear analysis
Kura Oncology (NASDAQ: CURA) is a biopharmaceutical company focused on developing innovative cancer therapies, particularly for acute myeloid leukemia (AML). With its lead product, Zipdementib, a next-generation menin inhibitor, Kura is positioned to address significant unmet medical needs in oncology. The company is transitioning toward commercialization of its therapies amid escalating competition in the menin inhibitor class. Kura's strategic initiatives point towards broadening treatment applications, exploring combination therapies, and solidifying its market presence as the urgency for effective cancer treatments becomes more pronounced.
Bull says
- ↑Q1 2026 ComSifty revenue $5.8M with 85 new patient starts.
- ↑2026 collaboration revenue guidance raised to $45–55M.
- ↑Cash & equivalents ~$667M secures runway into top-line Phase 3.
- ↑High institutional ownership and positive momentum underpin confidence.
- ↑Phase 3 data presentations at major oncology conferences serve as catalysts.
- ↑High-quality fundamentals relative to peers support growth outlook.
Bear says
- ↓Q1 net loss $73.3M vs $57.4M prior year signals widening deficits.
- ↓R&D spend climbed to $65.3M, pressuring free cash flow.
- ↓Negative earnings yield and weak profitability reflect margin challenges.
- ↓Intensifying menin inhibitor competition risks market share.
- ↓Negative EPS revisions denote declining analyst expectations.
- ↓Regulatory scrutiny on Ziftomenib could delay commercialization.
Investment themes with KURA
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- CUR is at an inflection point, and what we've been building over the last several years is now showing up clearly in the clinic, in the market, and in the way physicians are making treatment decisions.
- Our first commercial launch is off to a strong start, generating $5.8 million in net product revenue ahead of expectations.
- We're seeing repeat prescriptions. We're seeing broad uptake. and use expand across treatment centers. We're seeing increasing payer preference, and we're seeing early instances of physicians switching patients from other men and inhibitors to Comsifty.
Bear points
- Research and development expenses were $65.3 million compared to 56 million for the first quarter of 2025. The increase was driven by ZIPDOM and accommodation trials, including the start of enrollment in our COMET 017 trials in the second half of 2025.
- Selling, general, and administrative expenses were $31.6 million compared to $22.8 million for the first quarter of 2025.
- Net loss for the first quarter of 2026 was $73.3 million compared to a net loss of $57.4 million for the first quarter of 2025.